Tirzepatide and epigenetic clocks in a SURMOUNT-5 sub-study (conference description)
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedAccording to the conference description, a SURMOUNT-5 sub-study found that 72 weeks of tirzepatide slowed several epigenetic clocks, including organ-specific clocks, while some methylation-based predictions missed. This is a conference description; video and transcript were not reviewed. [1]
According to the description, 72 weeks of tirzepatide in a SURMOUNT-5 sub-study slowed multiple epigenetic clocks, including organ-specific clocks. [1]
The description states that some methylation-based predictions missed. [1]
The finding is attributed to Kevin Duffin of Eli Lilly, presenting at the 13th Aging Research and Drug Discovery Meeting. [1]
Tirzepatide in a SURMOUNT-5 sub-study
The description attributes the finding to Kevin Duffin of Eli Lilly, presenting at the 13th Aging Research and Drug Discovery Meeting. The key takeaway concerns a SURMOUNT-5 sub-study in which participants received tirzepatide, described as a dual agonist acting on GLP-1 and GIP, for 72 weeks. The description does not state how many people took part, who the comparator was or which outcomes were clinical. [1]
Slowed clocks, some predictions missed
According to the description, the 72 weeks of tirzepatide slowed multiple epigenetic clocks, including organ-specific clocks. Epigenetic clocks are described here only as methylation-based measures; the description does not explain them further. The same takeaway notes that some methylation-based predictions missed. The description gives no effect sizes, no numbers of clocks affected and no information on whether slowed clocks correspond to health outcomes. [1]
Conference description, not a study report
The supplied text is a conference description from the ARDD 2026 meeting, which the description says moved to Boston and took place on October 1–3, 2026. It lists organizers and supporters but gives no study methods, population details or statistics for the sub-study. The description therefore cannot show whether the clock changes reflect a health benefit. Video and transcript were not reviewed. [1]
Context & limits
This is a conference description only; video and transcript were not reviewed. It gives no sample size, comparator, effect sizes or clinical outcomes, and slowed clocks are not shown to mean health benefits.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
72 weeks of tirzepatide slowed multiple epigenetic
some methylation-based predictions missed
Kevin Duffin, Eli Lilly, presents at the
About this video
Creator description · original textText language: English
ARDD · 27 min · Source published: 2026-10-20
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.